NDAINJECTIONINJECTABLE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEFAZONE (cefmetazole sodium) is a second-generation cephalosporin antibiotic administered by injection for surgical prophylaxis and treatment of bacterial infections. It functions as a beta-lactam inhibitor targeting bacterial cell wall synthesis in gram-positive and gram-negative organisms.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30/100), indicating a defensive commercial strategy focused on market retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZEFAZONE offers exposure to hospital-based and specialty care commercialization, defensive marketing strategies, and mature product lifecycle management in a commoditized antibiotic market. Career growth may be constrained given zero linked job openings and approaching LOE, making this role better suited for professionals seeking stability or antibiotic-sector expertise rather than high-growth opportunities.
Brand Manager
Worked on ZEFAZONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.